Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R)

Cancer

Volumn 115, Issue 18, 2009, Pages 4136-4147

  Kantarjian, Hagop ^a   Pasquini, Ricardo ^b   Lévy, Vincent ^c   Jootar, Saengsuree ^d   Holowiecki, Jerzy ^e   Hamerschlak, Nelson ^f   Hughes, Timothy ^g   Bleickardt, Eric ^h   Dejardin, David ^h   Cortes, Jorge ^a   Shah, Neil P ⁱ  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Hospital de Clinicas de Curitiba   (Brazil)

^c SAINT LOUIS HOSPITAL   (France)

^d MAHIDOL UNIVERSITY   (Thailand)

^e University Hospital SPSKM   (Poland)

^f HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^g INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic myeloid leukemia; Dasatinib; Drug resistance; Imatinib

Indexed keywords

DASATINIB; IMATINIB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLUID RETENTION; HEADACHE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; WITHHOLDING TREATMENT;

EID: 70149105272     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24504     Document Type: Article

References (28)

1. National Comprehensive Cancer Network, Inc. The Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology. Version 1.2009. Available at http://www.nccn.org. Accessed August 29, 2008.
2. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820. (Pubitemid 44394987)
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
4. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007;357:258-265. (Pubitemid 47080390)
5. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year followup of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. (Pubitemid 44903745)
6. Hochhaus A, Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am. 2004;18:641-656. (Pubitemid 38969136)
7. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard- dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473-475. (Pubitemid 36077567)
8. Hochhaus A, Druker B, Sawyers C, et al. Favorable longterm follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008;111:1039-1043. (Pubitemid 351213381)
9. Jabbour E, Kantarjian H, Atallah E, et al. Impact of imatinib mesylate dose escalation on resistance and suboptimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML) [abstract]. Blood. 2007;110:313a-314a. Abstract 1035.
10. Kantarjian HM, Druker BJ, Guilhot F, et al. Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood. 2007;110:317a. Abstract 1047.
11. Marin D, Goldman JM, Olavarria E, et al. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood. 2003;102:2702-2703. (Pubitemid 37193621)
12. Zonder JA, Pemberton P, Brandt H, et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res. 2003;9:2092-2097. (Pubitemid 36687630)
13. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-4505.
14. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401. (Pubitemid 38938156)
15. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109:2303-2309. (Pubitemid 46425867)
16. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22:1200-1206. (Pubitemid 351833788)
17. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109:5143-5150. (Pubitemid 46890528)
18. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and - intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204-3212.
19. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib- resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541. (Pubitemid 43882349)
20. Mauro MJ, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol. 2008;26:374s. Abstract 7009. (Pubitemid 351833788)
21. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432. (Pubitemid 37211057)
22. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37. (Pubitemid 43990609)
23. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404-413.
24. Agresti A, Min Y. On small-sample confidence intervals for parameters in discrete distributions. Biometrics. 2001;57:963-971. (Pubitemid 32801196)
25. Brookmyer R, Crowley JJ. A confidence interval for the median survival time. Biometrics. 1982;38:29-41.
26. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa- 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337:223-229. (Pubitemid 27310437)
27. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358-3363.
28. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640-2653. (Pubitemid 40446252)